Members of the Beat AML consortium uncovered relationships between somatic mutations, gene expression profiles, and sensitivity to more than 100 drugs.
In combination with other clinical data, the genomic subtypes were able to predict patients' outcomes and could be used to help guide treatments.
The working group reviewed data to identify a minimum of 34 commonly mutated genes that should be included in pan-myeloid targeted panels.
The US Food and Drug Administration cleared Qiagen's Ipsogen JAK2 RGQ PCR Kit for additional use in the diagnosis of all myeloproliferative neoplasms
The test runs on Qiagen's Rotor-Gene Q MDx system and is designed to qualitatively detect the JAK2 V617F/G1849T allele in genomic DNA from whole blood.
The study expands on the known genetic subtypes, shows that they are correlated with clinical outcome, and paves the way for better subtype-driven patient management.
A multistage GWAS suggests inherited SNPs at four sites in the genome can contribute to the risk of developing myeloproliferative neoplasms.
Researchers have found that the order in which TET2 and JAK2 mutations are acquired may impact drug response and disease progression.
The 95-gene test is for detecting leukemia, myelodysplastic syndromes, and myeloproliferative disorders and can return results in less than one week.
Qiagen said this week that it has signed an agreement with Eli Lilly to develop a companion diagnostic for an early-stage compound that Lilly is developing to treat blood cancer.
The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.
The Associated Press reports that gene-edited food may soon be for sale.
The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.
In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.